Courage Therapeutics Inc.
Newton, MA
- UEI
- W841GEJ8ADX7
- CAGE
- 8EUM2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 64 Homer St, Newton, MA 02459, USA
- Website
- couragetx.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Velum Inc. | Cambridge, MA | — |
| Sapience Therapeutics, Inc. | Tarrytown, NY | — |
| Makscientific LLC | Burlington, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Camino Pharma LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Artiam Bio Inc. | Cary, NC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Courage Therapeutics Inc. is a pharmaceutical company dedicated to developing new medicines for eating disorders. Courage Therapeutics Inc. is registered as a corporate entity and self-certified small disadvantaged business eligible for federal contracts and grants.
Courage Therapeutics Inc. has received multiple federal grant awards from the Department of Health and Human Services' National Institutes of Health to develop melanocortin receptor peptide agonists and antagonists for the treatment of eating disorders like anorexia nervosa and obesity. Under the Mental Health Research Grants program, Courage was awarded $659,055 to design and test melanocortin-3 receptor (MC3R) agonist peptides to stimulate food intake and weight gain for anorexia treatment. The National Institute of Diabetes and Digestive and Kidney Diseases awarded Courage $2.5 million to develop novel MC4R agonist peptides for obesity caused by MC4R deficiency, a condition current drugs cannot treat effectively. Courage also received $244,905 to develop MC3R antagonist peptides for treating obesity by inhibiting MC4R neurons involved in appetite regulation. The expected outcomes include patentable lead candidates, preclinical testing, and potential clinical trials for these therapeutic peptides targeting melanocortin receptors implicated in eating and weight disorders.
Quick answers
Is Courage Therapeutics Inc. registered in SAM.gov?
Yes. Courage Therapeutics Inc.'s SAM.gov registration is active through August 20, 2027.
What is Courage Therapeutics Inc.'s most recent federal award?
Courage Therapeutics Inc.'s most recent federal grant award is Development of melanocortin-3 receptor peptide agonists for the treatment of anorexia nervosa - anorexia nervosa (an)… (R41MH124449), from National Institute of Mental Health (NIH), on May 1, 2021.
On GovTribe
See Courage Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors